Lexel – Nestor Rava, CEO – Argentina
The CEO and one of the founders of Lexel explains how the company adapts its medical devices to the specifications required by their international customers. Why did Lexel enter…
Bioceres is an Argentina-based firm that manages investments in agricultural biotechnology and related sciences. It was founded in December 2001 by 23 farmers and is now owned by more than 270 shareholders, most of them innovative farmers but also coops and different actors from the agro-industrial sector. Every year, Bioceres shareholders plant about 2.5 million hectares in different regions of Latin America.
Since its beginnings, Bioceres has been a bridge between the scientific community and the agricultural production sector, fostering public-private associations and the development of collaborative networks.
Bioceres is a firm open to new shareholders with a shared dream-developing new technologies that help us use natural resources in a more efficient way while increasing and stabilizing the productivity of ecosystems.
Bioceres goes from genes to seeds, linking the laboratory to the field, adding value in every stage, and building and strengthening public-private partnerships.
CONTACT DETAILS
Ocampo 210 bis, predio CCT Rosario, (2000) Rosario, Santa Fe, Argentina
Phone: (54) 341 486 1100 Fax:(54) 341 486 1100
The CEO and one of the founders of Lexel explains how the company adapts its medical devices to the specifications required by their international customers. Why did Lexel enter…
Carlos Chiale, National Administrator of ANMAT, discusses the agency’s latest strategy implementation and its pioneering work in the area of fighting drug falsification. Could you provide a historical overview…
The general manager of Sandoz South Latam weighs up the factors that have allowed his company to be the leader in biosimilars and differentiated generics. Could you please…
The vice president of Laboratorios Beta discusses the factors of why his organization is on the way to consolidating its different business lines and becoming a pure pharmaceutical company. …
The general director of pharma in Argentina for the Bagó group explains why his group has planned that 75 percent of turnover will come from international markets in the coming years. 2014 marks…
The executive coordinator of GACTEC maps the current level of science and technology in Argentina and outlines the country’s ambitions in this area, which is to have an impact on innovation at…
The President of Argenomics highlights the position of his company as the bridge between science and business in Argentina. Could you please provide an historical overview of Argenomics? Several…
The general manager of Ferring Argentina believes that the country has one of the strongest social security systems in Latin America, with high reimbursement levels and coverage for most chronic…
The general manager of Roche Argentina weighs up the factors that have allowed the country to be included among the top three performing markets in the region for Roche, and…
The general manager of Gennoma Laboratorios Argentina weighs up the factors of why raising brand awareness using public television is the key success to his company communication strategy. When…
“In the last decade, as a result of high and sustained growth, the Argentine pharmaceutical industry increased production by more than 240 percent, which speaks volumes about the capacity of…
The country president of AstraZeneca Argentina discusses the country’s patent laws, the work being done to bring innovation back to Argentina, and the challenge of a strong branded generics market…
See our Cookie Privacy Policy Here
